I don’t! I think the rationale behind the question is that tafasitamab has to be given with lenalidomide which has been shown to be more efficacious in non-GCB DLBCL. The rationale of combining lenalidomide with tafasitamab has more to do with expansion of NK cells to augment tafasitamab-media...